Shares of AstraZeneca Pharma India today surged over 10 per cent after the company said it has received approval from the country's drug regulator to market Durvalumab, a cancer treatment medicine.
The stock zoomed 9.32 per cent to settle at Rs 1,478.55 on BSE. During the day, it soared 10.97 per cent to Rs 1,501.
At NSE, shares of the company jumped 10.14 per cent to close at Rs 1,487.
The company has received import and market permission for Durvalumab from the Drug Controller General of India (DCGI), AstraZeneca Pharma India said in a statement yesterday.
The approval paves the way for the company to launch the product in the country, it added.
Durvalumab is indicated as a treatment option for patients with locally advanced, unresectable non-small cell lung Cancer (NSCLC) and metastatic urothelial carcinoma.
Disclaimer: No Business Standard Journalist was involved in creation of this content
